Fig. 3From: PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancersThe influence of PARP inhibitors and BRCA mutation status in DNA repair and apoptosis of cancer cell. (Note: SSB, single strand break; BER, base excision repair; DSB, double strand break; HRR, homologous recombination repair; NHEJ, Non-homologous end-joining)Back to article page